Treatment of bowel in experimental gastroschisis with a nitric oxide donor




Objective


To reduce the harmful effect of bowel exposure to amniotic fluid in gastroschisis, we used the nitric oxide (NO) donor S-nitrosoglutathione (GSNO) in an animal model of gastroschisis and assessed the ideal concentration for treatment of changes in bowel.


Study Design


Gastroschisis was surgically induced in rat fetuses on day 18.5 of gestation. The fetuses were divided into 5 groups (n = 12 animals/group): control (C), gastroschisis (G), gastroschisis + GSNO 5 μmol/L (GNO1), gastroschisis + GSNO 0.5 μmol/L (GNO2), and gastroschisis + GSNO 0.05 μmol/L (GNO3). On day 21.5 of gestation, fetuses were collected by cesarean delivery. Body and intestinal weight were measured and the bowels were either fixed for histometric and immunohistochemical study or frozen for Western blotting. We analyzed bowel morphometry on histological sections and expression of the NO synthase (NOS) enzymes by Western blotting and immunohistochemistry. Data were analyzed by analysis of variance or Kruskal-Wallis test when appropriate.


Results


Morphological and histometric measurements of weight, diameter, and thickness of the layers of the intestinal wall decreased with GSNO treatment, especially in the GNO3 group, when compared with the G group ( P < .05). The expression of neuronal NOS, endothelial NOS, and inducible NOS decreased mainly in GNO3 group compared to the G group ( P < .05), with no difference compared to C group ( P > .05).


Conclusion


Fetal treatment with 0.05 μmol/L GSNO resulted in significant improvement of bowel morphology in gastroschisis.


Gastroschisis is a congenital defect of the abdominal wall, which allows herniation and permanent exposure of the bowel to the amniotic fluid during pregnancy. This exposure leads to intestinal hypomotility and malabsorption, requiring parenteral nutrition and increasing morbidity, mortality, and cost of medical treatment.


Histological and physiological changes in gastroschisis are associated with local concentration and production of nitric oxide (NO) by the NO synthases (NOS), such as neuronal NOS (nNOS), endothelial NOS (eNOS), and inducible NOS (iNOS), and is considered to be essential for normal gastrointestinal physiology due to NO involvement in the modulation of mucosal permeability, muscle motility, and viability of epithelial cells. Experimental models of gastroschisis using rabbits and chickens showed that the increased activity of NOS is directly related to increased inflammation of the bowel, but causality has not been established.


NO is an important element among the many agents produced by the various cells involved in wound healing. The beneficial actions of NO in wound healing may include local vasodilation through the modulation of cyclic 3′,5′-guanosine monophosphate, inhibition of platelet aggregation and thrombosis, inhibition of smooth muscle cell proliferation (and stenosis), promotion of angiogenesis, reendothelization, and antimicrobial action.


S-nitrosoglutathione (GSNO) has already been identified as an endogenous NO carrier and donor in mammals and has been at the center of several pharmacological studies investigating the importance of NO in living systems. GSNO can decompose spontaneously through homolytic bond cleavage, with free NO release and the formation of oxidized glutathione. Incorporation of GSNO in nontoxic polymers allows local delivery of NO to target areas where NO may have a vasodilator or antiinflammatory effect. Therefore, the aim of our study was to evaluate the effect and the best concentration of GSNO in the treatment of bowel in fetal gastroschisis.


Materials and Methods


Synthesis of GSNO


GSNO was synthesized by reacting equimolar gluthatione with sodium nitrite in acidic aqueous solutions (chloridric acid 0.5 mol/L, pH 1) as described previously. The compound was diluted in sterile Milli-Q (Merck KGaA, Darmstadt, Germany) water so that the concentrations were 0.01, 0.001, and 0.0001 mmol/L. In each fetus a final volume of 30 μL was applied, thus the final GSNO concentrations were 5, 0.5, and 0.05 μmol/L, respectively.


Animals and groups


This study was submitted to and approved by the Animal Experimentation Ethics Committee of University of Campinas (research project no. 1452-1). Female Sprague Dawley (CEMIB-Unicamp Campinas, São Paolo, Brazil) rats weighing 250-300 g were time mated and the day following mating was considered day 0 of pregnancy after observation of spermatozoids in the vaginal smear (gestation length = 22 days). The animals received chow and water ad libitum, in controlled lighting, temperature, and humidity environment.


The fetuses (n = 60) were divided in 5 groups of 12 fetuses: control (C), gastroschisis (G), gastroschisis + GSNO 5 μmol/L (GNO1), gastroschisis + GSNO 0.5 μmol/L (GNO2), and gastroschisis + GSNO 0.05 μmol/L (GNO3). Besides the above groups, in each pregnant rat operated on, in addition to the gastroschisis group, we had fetuses that were not manipulated (internal control), fetuses that were manipulated with hysterotomy and exteriorized (group sham), as well as internal control fetuses for each NO dose used.


Surgical procedure


Surgery was performed at 18.5 days of gestation. Pregnant rats were anesthetized with ketamine 50 mg/mL (175 mg/kg) (Ketamina Agener; União Química Farmacêutica Nacional S/A, São Paulo, Brazil) associated with xylazine 10 mg/mL (2.5 mg/kg) (Dopaser- Laboratórios Calier S/A, Barcelona, Spain). Their abdominal cavity was opened by median laparotomy in 2 layers. Fetuses were counted from the uterine isthmus and gastroschisis was created on the second fetus in each cornus. Fetuses for the C group were obtained from pregnant rats that were not subjected to surgery.


Gastroschisis was created according to the technique described by Correia-Pinto et al. The lower body of the fetus was exposed and a right paraumbilical incision was performed with exposure of the intestine. In the G group, after creation of gastroschisis, the fetus was carefully placed back in the uterine cavity and the uterus was closed. In the fetuses that received 30 μL of GSNO, the material was applied to the bowel and then the fetus was placed back in the uterine cavity. During the procedure the uterus and the fetus were kept warm by instillation of normal saline solution at 38°C. At the end of the procedure the maternal abdominal wall was closed and supplemental oxygen at 1 L/min was provided during recovery from anesthesia.


Sample harvesting


At 21.5 days of gestation, pregnant rats were anesthetized and underwent cesarean delivery. Fetuses were removed from the uterine cavity, euthanized, and their body weight (BW) was measured. The intestinal tract was resected from the pylorus to the rectum and weighted; intestinal weight (IW) and the IW/BW ratio was calculated. The samples were fixed in 4% paraformaldehyde for morphometric and immunohistochemical analysis or snap frozen at –80°C for Western blotting.


Morphometric and histological analysis


We standardized analysis of the intermediate (jejuno-ileal) segments only. After fixing, the samples were dehydrated in ethanol, diaphanyzed in xylene, and embedded in paraffin. Transversal histological sections of 5 μm were obtained and stained with hematoxylin-eosin for histological analysis. Slides were photographed using a photodocumentation microscope (Eclipse E200 80 i ; Nikon, Tokyo, Japan). A magnification of ×20 was used for measurement of the intestinal diameter and ×200 for measurement of the thickness of intestinal layers, including intestinal wall thickness, mucosa and submucosa, circular muscular, longitudinal muscular, and serosa. Measurements were obtained with the software (Image Pro Plus 6.0; Media Cybernetics Inc, Rockville, MD). All the measurements were performed in radial orientation in the 4 quadrants of 5 sequential nonoverlapping sections for each fetus.


Immunohistochemistry


Histological sections obtained in paraffin were deparaffinized in xylene and rehydrated in ethanol. Then, antigen exposure was performed with sodium borate (0.1 mol/L, pH 7.4) for 1 hour at room temperature. The endogenous peroxidases were eliminated with 10% hydrogen peroxide in phosphate-buffered saline solution (PBS) (0.01 mol/L, pH 7.4) for 30 minutes. Blocking was performed with 1% bovine serum albumin (BSA) in PBS for 1 hour. Sections were incubated with anti-nNOS, anti-iNOS, or anti-eNOS diluted 1:200 in PBS/BSA 3% (sc-648, sc-651, and sc-654, respectively; Santa Cruz Biotechnology, Santa Cruz, CA) overnight at 4°C. On the second day, sections were washed and incubated with peroxidase conjugated secondary antibody antirabbit raised in goat (sc-2004; Santa Cruz Biotechnology) diluted 1:2000 in PBS/BSA 1% for 1 hour. Then, sections were treated with Vectastain ABC kit (Vector Laboratories, Burlingame, CA) and 3,3 = -diaminobenzidine tetrahydrochloride hydrated (Sigma-Aldrich, St. Louis, MO). As negative control the primary antibody was omitted in one of the slides. Sections were then stained with Harris hematoxylin, dehydrated, and mounted. Slides were analyzed independently and blindly by 2 investigators using a semiquantitative scale ranging from 0-3: grade 0 = no staining; grade 1 = faint staining; grade 2 = moderate staining; and grade 3 = strong staining.


Western blotting


The bowel from 6 animals per group was homogenized in 1 mL of extraction buffer containing: Tris 100 nmol/L (pH 7.4), sodium pyrophosphate 100 nmol/L, sodium fluoride 100 nmol/L, EDTA 10 nmol/L, sodium vanadate 10 nmol/L, and phenylmethylsulfonyl fluoride 2 nmol/L, and aprotinin 0.1 mg/mL, and 1% Triton- X100 at 4°C with a tissue homogenizer (Tecnal, Paulinia, Brazil) operated at maximum speed for 30 seconds. The extracts were centrifuged at 14,000 rpm (9000 g ) at 4°C in a Mikro 200R centrifuge (Hettich, Tuttlingen, Germany) for 30 minutes to remove insoluble material, and the supernatants of these tissues were used for protein quantification using the Bradford method. Then proteins were denatured, run on polyacrylamide gel, and transferred to nitrocellulose membranes. Nonspecific binding sites were blocked with 0.2% BSA in PBS (0.01 mol/L, pH 7.4) for 1 hour. Then, membranes were incubated with anti-nNOS, anti-iNOS, or anti-eNOS diluted 1:200 in PBS/BSA 3% (sc-648, sc-651, and sc-654, respectively; Santa Cruz Biotechnology) overnight at 4°C.


The next day, after washing, the membranes were incubated with peroxidase conjugated secondary antibody antirabbit raised in goat (sc-2004; Santa Cruz Biotechnology) diluted 1:5000 in PBS/BSA 3% for 2 hours. Membranes were then treated with chemoluminescence kit (Pierce, Rockville, IL), exposed to radiographic films (Kodak, Rochester, NY), and developed.


Statistical analysis


Weights and morphometric values were obtained and Western blotting data were analyzed by analysis of variance with Tukey-Kramer posttest. Immunostaining grading was analyzed by Kruskal-Wallis test with Dunn posttest. We used the software GraphPad Prism 5.0 (GraphPad Software Inc, La Jolla, CA). Significance was established for a P value < .05.




Results


The overall mortality rate was 12%. The G group had the highest rate of 41%, followed by 25% on the GNO1 group, 19% on the GNO2 group, and 16% on the GNO3 group.


The BW, IW, and IW/BW ratio are shown in the Table . The BW in the C group was higher when compared to all the other groups ( P < .001). The IW and IW/BW ratio in the C group was not significantly different from the other groups ( P > .05).



Table

Distribution of values of BW, IW, and IW/BW ratio relationship for all study groups, expressed as mean ± SD


































Variable BW, g IW, g IW/BW ratio, %
C 5.92 ± 0.51 a 0.18 ± 0.02 3.00 ± 0.24
G 4.39 ± 0.84 0.21 ± 0.04 4.80 ± 0.86
GNO1 4.55 ± 0.73 0.22 ± 0.04 4.83 ± 0.88
GNO2 4.53 ± 0.73 0.18 ± 0.05 4.02 ± 0.95
GNO3 4.09 ± 0.64 0.17 ± 0.05 4.04 ± 0.85

BW , body weight; IW , intestinal weight.

Gonçalves. Bowel treatment with nitric oxide donor in gastroschisis. Am J Obstet Gynecol 2015 .

a P < .001 compared with others groups.



The histometric analysis is shown in Figure 1 . The intestinal diameter was increased in the G group compared to the C group, while the GNO3 group showed reduction in the intestinal diameter when compared to G group ( P < .001) and no difference when compared to C group ( P > .05). The intestinal wall thickness of all intervention groups were increased compare to the C group ( P < .05), but all of the GSNO-treated groups were decreased compared to the G group ( P < .05). The mucosa and submucosa layers were similar among the 3 GSNO groups and G group ( P > .05). The circular and longitudinal muscle layers decreased in GNO3 group when compared to the G group ( P < .05) and, finally, the serosa layer in C group was similar to GNO3 group ( P < .05).




Figure 1


Results of intestinal morphometric analysis

A , Diameter. B , Intestinal wall thickness. C , Serous. D , Longitudinal muscle layer. E , Circular muscle layer. F , Mucosa and submucosa layers. Control (C), gastroschisis (G), gastroschisis + GSNO 5 μmol/L (GNO1), gastroschisis + GSNO 0.5 μmol/L (GNO2), and gastroschisis + GSNO 0.05 μmol/L (GNO3). Compared with groups: a G, b GNO1, c GNO2, and d GNO3.

P < .05; ∗∗ P < .001.

Gonçalves. Bowel treatment with nitric oxide donor in gastroschisis. Am J Obstet Gynecol 2015 .


Immunohistochemistry results are shown in Figures 2 and 3 . We saw that the main differences were that all the treated groups had decreased nNOS, iNOS, and eNOS expression when compared to the G group ( P < .05). For the 3 isoforms, the C group was different from G, GNO1, and GNO2 groups ( P < .001) and only the GNO3 group had no difference when compared to the C group ( P > .05).


May 6, 2017 | Posted by in GYNECOLOGY | Comments Off on Treatment of bowel in experimental gastroschisis with a nitric oxide donor

Full access? Get Clinical Tree

Get Clinical Tree app for offline access